Nucleoside/nucleotide drugs tend to have safety issues. If they didn’t, every company would have one that works well. Efficacy as a polymerase (or reverse-transcriptase) chain blocker is relatively easy to engineer, and these compounds are among the simplest small-molecule drugs.
You're assuming whoever tweeted that is correct. Here's one of the 189 trials. Perhaps it was in the non-daclatasvir arm. I don't recall cardiovascular issues being a side effect of ribavarin.
Market Data 
Markets 
AI
